Why the Mach7 (ASX:M7T) share price is roaring 6% higher today

Mach7's revenues are set for a much welcomed boost.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Mach7 Technologies Ltd (ASX: M7T) share price is pushing firmly into positive territory on Tuesday. This comes after the healthcare imaging platform provider announced new sales to an existing client.

At the time of writing, Mach7 shares are up 6.53% to a 2-month high of $1.06.

Two doctors smile as they sit together at a desk looking at a patient's x-ray.

Image source: Getty Images

Mach7 secures purchase orders

While the All Ordinaries Index (ASX: XAO) has fallen 0.63% to 7,338 points, the Mach7 share price has headed north.

According to its announcement, Mach7 advised it has received purchase orders from Trinity Health for an array of its products. These include Mach7 Enterprise Imaging Platform, eUnity Diagnostic Viewer, eUnity Enterprise Viewer, and Mach7 Universal Worklist.

Based in Michigan, Trinity Health is one of the largest multi-institutional Catholic health care delivery systems in the United States. The company services 92 hospitals, as well as 100 continuing care locations that provide care programs and senior living facilities for the elderly.

Mach7 noted the initial purchase orders have a combined value of $3.6 million for software and services. The revenues are expected to be recognised in the current financial year.

In addition, following software deployment, the orders will contribute another $3.8 million in support fees over the next 7 years. In total, this brings the initial contract value to $7.4 million for Mach7.

Mach7 CEO Mike Lampron commented:

I am excited for the opportunity to [partner] with Trinity Health, one of the top healthcare delivery networks in the United States.

I believe the full Mach7 solution is well-positioned to deliver on the strategic objectives of Trinity's Unified Clinical Imaging Platform Strategy and I look forward to being a part of their initiative.

About the Mach7 share price

Over the past 12 months, Mach7 shares have moved sideways to register a 5% loss for the period. Year-to-date also hasn't been great for investors with the company's shares down more than 15% despite today's gain.

Based on the current share price, Mach7 commands a market capitalisation of roughly $251 million with 236.8 million shares outstanding.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended MACH7 FPO. The Motley Fool Australia has recommended MACH7 FPO. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Man with a sleep apnoea mask on whilst sleeping.
Healthcare Shares

Why ResMed shares are tumbling 6% today despite strong results

Here's what spooked investors.

Read more »

Scientist looking at a laptop thinking about the share price performance.
Healthcare Shares

Imricor Medical Systems shares: Philips declares compatibility for iMR products

Big news is catching the eye of investors on Friday.

Read more »

Broker looking at the share price on her laptop with green and red points in the background.
Earnings Results

ResMed posts strong Q4 earnings, lifts dividend

The sleep disorder treatment company had another record quarter.

Read more »

a doctor wearing a white coat with a stethoscope around her neck stares out a window with her hand to the side of her face as though in deep thought.
Healthcare Shares

Clarity Pharmaceuticals reports clinical trial milestones

Clarity Pharmaceuticals reported continued clinical progress for its prostate cancer imaging and therapy programs.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

Are Neuren Pharmaceuticals shares a buy, hold or sell after rocketing 16%?

This healthcare stock keeps rising.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Broker Notes

Up 64%, 3 reasons this expert predicts Pro Medicus shares will keep on giving

A leading expert forecasts more outperformance from the surging Pro Medicus share price.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Clarity Pharmaceuticals reports new SECuRE trial responses at higher dose

Clarity Pharmaceuticals reports further progress in its SECuRE prostate cancer trial, showing strong PSA responses and new complete responses at…

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Neuren Pharmaceuticals share price rockets: record Q2 DAYBUE sales and royalty upgrade

Second quarter net sales of DAYBUE increased 30%.

Read more »